Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs
Overview
US biotech firm's 2025 net loss widenes, R&D expenses increased for clinical programs
Company secured FDA Orphan Drug designation for tegoprubart in liver transplantation
Result Drivers
R&D SPENDING - Higher R&D expenses driven by expanded clinical trial activity, manufacturing scale-up and increased personnel for tegoprubart programs
LOWER ADMIN COSTS - General and administrative expenses fell due to lower stock-based compensation, partially offset by higher professional services and personnel costs
Company press release: ID:nGNX4sMTZX
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Net Income |
| -$45.62 mln |
|
FY Operating Expenses |
| $83.25 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Eledon Pharmaceuticals Inc is $8.50, about 183.3% above its March 18 closing price of $3.00
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
